6-K - RDY - Equibles

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

March, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

ExhibitNumber	Description of Exhibits
rdy0860_ex99-1.htm99.1	Intimation dated March 17, 2026
2
---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED<br><br>(Registrant)
Date: March 17, 2026	By:	/s/ K Randhir Singh
		Name: K Randhir Singh
		Title: Company Secretary
3
---

Exhibit 99.1

Dr. Reddy's Laboratories Ltd .<br><br>8-2-337, Road No. 3, Banjara Hills<br><br>Hyderabad – 500 034, Telangana, India<br><br><br><br>CIN: L85195TG1984PLC004507<br><br><br><br>Tel: + 91 40 4900 2900<br><br>Fax: + 91 40 4900 2999<br><br>Email: mail@drreddys.com<br><br>Web: www.drreddys.com

March 17, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Ref:	Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform that the Company has received three separate orders from GST Authority towards tax demand including interest and penalty for the period FY 2019-20 to FY 2021-22. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:

Name of the authority	:	Commercial Taxes Department – Office of the Joint Commissioner (ST), Chennai Intelligence -II.
Nature and details of the action(s) taken, or order(s) passed	:	The Company has received order seeking demand including interest and penalty under section 74 of the TNGST Act, 2017.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	:	Orders dated March 16, 2026, were received by the Company on March 16, 2026.
Details of the violation(s)/ contravention(s) committed or alleged to be committed	:	The authority has passed the orders primarily on the ground that certain supplies are taxable in nature.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	:	The above orders levy penalty as detailed below:
			Financial Year	Penalty
			FY 2019-20	2,19,48,944/-
			FY 2020-21	50,406/-
			FY 2021-22	4,384/-
		Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company.

The Company will evaluate filing necessary appeal with the appellate authority in this regard.

This is for your information and records.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR